Stoke Therapeutics, Inc. (STOK) — closed signal from December 14, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 14, 2026.
Predicted vs. what happened
What happened
Hit or exceeded the predicted growth inside the window.
The thesis — published December 14, 2025
This is a short-term biotech trade driven by news. Positive long-term data for the drug in Dravet syndrome and an after-hours price jump are attracting buyers despite an insider-related share sale. recent technical signals suggest buying on small pullbacks, but trading volume is low so the price can jump sharply - position size small and use tight stops.
Primary drivers
- Good clinical results keep investors watching
- Sentiment swings can move biotech stocks fast
- Recent technical signals support buying small dips
- News-heavy trading can amplify gains and losses quickly
How it played out
STOK: the target was not reached
Lyra published STOK at $32.39 on December 14, 2025. The thesis expected 30% growth to $42.11. It pointed to good clinical results, sentiment swings in biotech stocks, technical signals around small dips, and news-heavy trading that could amplify gains and losses.
Inside the window, STOK rose as high as $40.22 on March 10, 2026, a 24.2% peak gain. It stayed below the $42.11 target and never got there. The stock ended the window at $33.19. The thesis partially played out, but the published target was missed.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.